Dabocemagene Autoficel

Summary

Dabocemagene Autoficel (CHEMBL4650267) is a phase-3 clinical-stage gene; indicated across 2 conditions including epidermolysis bullosa dystrophica.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650267
Name	Dabocemagene Autoficel
Type	Gene
Max phase	3

Also known as: Dabocemagene autoficel, FCX-007, DABOCEMAGENE AUTOFICEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
epidermolysis bullosa dystrophica	3	MONDO:0006543	MONDO:0009179

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02810951	PHASE1/PHASE2	TERMINATED	A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).